{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:27:40Z","timestamp":1787135260509,"version":"build-2736575974"},"reference-count":285,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10364-9","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:53:36Z","timestamp":1787129616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion"],"prefix":"10.1007","volume":"45","author":[{"given":"Hesham M.","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Aminnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona M.","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"12","key":"10364_CR1","doi-asserted-by":"publisher","first-page":"9526","DOI":"10.1074\/jbc.M007333200","volume":"276","author":"B Souttou","year":"2001","unstructured":"Souttou, B., Carvalho, N. B., Raulais, D., & Vigny, M. (2001). Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. Journal of Biological Chemistry, 276(12), 9526\u20139531.","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10364_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.06.040","volume":"146","author":"LY Cheng","year":"2011","unstructured":"Cheng, L. Y., Bailey, A. P., Leevers, S. J., Ragan, T. J., Driscoll, P. C., & Gould, A. P. (2011). Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila. Cell, 146(3), 435\u201347.","journal-title":"Cell"},{"issue":"4","key":"10364_CR3","first-page":"E630","volume":"115","author":"A Fadeev","year":"2018","unstructured":"Fadeev, A., Mendoza-Garcia, P., Irion, U., Guan, J., Pfeifer, K., Wiessner, S., et al. (2018). ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells. Proceedings of the National Academy of Sciences of the United States of America, 115(4), E630-e8.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10364_CR4","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg, B., & Palmer, R. H. (2016). The role of the ALK receptor in cancer biology. Annals of Oncology, 27, iii4\u2013iii15.","journal-title":"Annals of Oncology"},{"issue":"4","key":"10364_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.onc.1200849","volume":"14","author":"T Iwahara","year":"1997","unstructured":"Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 14(4), 439\u201349.","journal-title":"Oncogene"},{"issue":"18","key":"10364_CR6","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","volume":"14","author":"SW Morris","year":"1997","unstructured":"Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., et al. (1997). ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin\u2019s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene, 14(18), 2175\u201388.","journal-title":"Oncogene"},{"issue":"32","key":"10364_CR7","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.1021\/bi1005514","volume":"49","author":"RT Bossi","year":"2010","unstructured":"Bossi, R. T., Saccardo, M. B., Ardini, E., Menichincheri, M., Rusconi, L., Magnaghi, P., et al. (2010). Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry, 49(32), 6813\u20136825.","journal-title":"Biochemistry"},{"issue":"3","key":"10364_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/BJ20100609","volume":"430","author":"CC Lee","year":"2010","unstructured":"Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., et al. (2010). Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochemical Journal, 430(3), 425\u201337.","journal-title":"Biochemical Journal"},{"issue":"23","key":"10364_CR9","doi-asserted-by":"publisher","first-page":"8533","DOI":"10.1021\/bi0472954","volume":"44","author":"A Donella-Deana","year":"2005","unstructured":"Donella-Deana, A., Marin, O., Cesaro, L., Gunby, R. H., Ferrarese, A., Coluccia, A. M., et al. (2005). Unique substrate specificity of anaplastic lymphoma kinase (ALK): Development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry, 44(23), 8533\u20138542.","journal-title":"Biochemistry"},{"issue":"7","key":"10364_CR10","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1074\/jbc.M706067200","volume":"283","author":"CJ Tartari","year":"2008","unstructured":"Tartari, C. J., Gunby, R. H., Coluccia, A. M., Sottocornola, R., Cimbro, B., Scapozza, L., et al. (2008). Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. Journal of Biological Chemistry, 283(7), 3743\u201350.","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10364_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.febslet.2007.01.039","volume":"581","author":"J Degoutin","year":"2007","unstructured":"Degoutin, J., Vigny, M., & Gouzi, J. Y. (2007). ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation. FEBS Letters, 581(4), 727\u2013734.","journal-title":"FEBS Letters"},{"issue":"6","key":"10364_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.onc.1209840","volume":"26","author":"AH Kuo","year":"2007","unstructured":"Kuo, A. H., Stoica, G. E., Riegel, A. T., & Wellstein, A. (2007). Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene, 26(6), 859\u2013869.","journal-title":"Oncogene"},{"issue":"3","key":"10364_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1586\/14737140.9.3.331","volume":"9","author":"TR Webb","year":"2009","unstructured":"Webb, T. R., Slavish, J., George, R. E., Look, A. T., Xue, L., Jiang, Q., et al. (2009). Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Review of Anticancer Therapy, 9(3), 331\u201356.","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"19","key":"10364_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167158","volume":"433","author":"E U\u00e7kun","year":"2021","unstructured":"U\u00e7kun, E., Siaw, J. T., Guan, J., Anthonydhason, V., Fuchs, J., Wolfstetter, G., et al. (2021). BioID-screening identifies PEAK1 and SHP2 as components of the ALK proximitome in neuroblastoma cells. Journal of Molecular Biology, 433(19), Article 167158.","journal-title":"Journal of Molecular Biology"},{"issue":"5","key":"10364_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","volume":"25","author":"C Voena","year":"2025","unstructured":"Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025). ALK in cancer: From function to therapeutic targeting. Nature Reviews Cancer, 25(5), 359\u2013378.","journal-title":"Nature Reviews Cancer"},{"issue":"19","key":"10364_CR16","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1021\/jm060380k","volume":"49","author":"RH Gunby","year":"2006","unstructured":"Gunby, R. H., Ahmed, S., Sottocornola, R., Gasser, M., Redaelli, S., Mologni, L., et al. (2006). Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. Journal of Medicinal Chemistry., 49(19), 5759\u20135768.","journal-title":"Journal of Medicinal Chemistry."},{"key":"10364_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113448","author":"H Huang","year":"2018","unstructured":"Huang, H. (2018). Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: A catalytic receptor with many faces. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms19113448","journal-title":"International Journal of Molecular Sciences"},{"key":"10364_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-026-03977-4","author":"HC Oh","year":"2026","unstructured":"Oh, H. C., Han, Y., Chang, Y., & Kim, H. H. (2026). A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. Genome Biology. https:\/\/doi.org\/10.1186\/s13059-026-03977-4","journal-title":"Genome Biology"},{"issue":"39","key":"10364_CR19","doi-asserted-by":"publisher","first-page":"28683","DOI":"10.1074\/jbc.M704505200","volume":"282","author":"P Perez-Pinera","year":"2007","unstructured":"Perez-Pinera, P., Zhang, W., Chang, Y., Vega, J. A., & Deuel, T. F. (2007). Anaplastic lymphoma kinase is activated through the pleiotrophin\/receptor protein-tyrosine phosphatase \u03b2\/\u03b6 signaling pathway. Journal of Biological Chemistry., 282(39), 28683\u201328690.","journal-title":"Journal of Biological Chemistry."},{"issue":"12","key":"10364_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cellsig.2007.07.011","volume":"19","author":"T Mathivet","year":"2007","unstructured":"Mathivet, T., Mazot, P., & Vigny, M. (2007). In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cellular Signalling, 19(12), 2434\u20132443.","journal-title":"Cellular Signalling"},{"key":"10364_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09811","volume":"4","author":"J Guan","year":"2015","unstructured":"Guan, J., Umapathy, G., Yamazaki, Y., Wolfstetter, G., Mendoza, P., Pfeifer, K., et al. (2015). FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. eLife, 4, Article e09811.","journal-title":"eLife"},{"issue":"45","key":"10364_CR22","doi-asserted-by":"publisher","first-page":"12027","DOI":"10.1073\/pnas.1710254114","volume":"114","author":"ES Mo","year":"2017","unstructured":"Mo, E. S., Cheng, Q., Reshetnyak, A. V., Schlessinger, J., & Nicoli, S. (2017). Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proc Natl Acad Sci U S A., 114(45), 12027\u201312032.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7887","key":"10364_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41586-021-04140-8","volume":"600","author":"AV Reshetnyak","year":"2021","unstructured":"Reshetnyak, A. V., Rossi, P., Myasnikov, A. G., Sowaileh, M., Mohanty, J., Nourse, A., et al. (2021). Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature, 600(7887), 153\u2013157.","journal-title":"Nature"},{"issue":"3","key":"10364_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.pbb.2011.10.024","volume":"100","author":"JB Weiss","year":"2012","unstructured":"Weiss, J. B., Xue, C., Benice, T., Xue, L., Morris, S. W., & Raber, J. (2012). Anaplastic lymphoma kinase and leukocyte tyrosine kinase: Functions and genetic interactions in learning, memory and adult neurogenesis. Pharmacology Biochemistry and Behavior, 100(3), 566\u2013574.","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10364_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fphar.2017.00533","volume":"8","author":"RA Mangieri","year":"2017","unstructured":"Mangieri, R. A., Maier, E. Y., Buske, T. R., Lasek, A. W., & Morrisett, R. A. (2017). Anaplastic lymphoma kinase is a regulator of alcohol consumption and excitatory synaptic plasticity in the nucleus accumbens shell. Frontiers in Pharmacology, 8, 533.","journal-title":"Frontiers in Pharmacology"},{"issue":"40","key":"10364_CR26","doi-asserted-by":"publisher","first-page":"14134","DOI":"10.1523\/JNEUROSCI.3415-11.2011","volume":"31","author":"AW Lasek","year":"2011","unstructured":"Lasek, A. W., Gesch, J., Giorgetti, F., Kharazia, V., & Heberlein, U. (2011). Alk is a transcriptional target of LMO4 and ER\u03b1 that promotes cocaine sensitization and reward. Journal of Neuroscience, 31(40), 14134\u201314141.","journal-title":"Journal of Neuroscience"},{"key":"10364_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154317","author":"M Defaye","year":"2022","unstructured":"Defaye, M., Iftinca, M. C., Gadotti, V. M., Basso, L., Abdullah, N. S., Cum\u00e9nal, M., et al. (2022). The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain. Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI154317","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10364_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.modgep.2005.11.006","volume":"6","author":"E Vernersson","year":"2006","unstructured":"Vernersson, E., Khoo, N. K., Henriksson, M. L., Roos, G., Palmer, R. H., & Hallberg, B. (2006). Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expression Patterns, 6(5), 448\u2013461.","journal-title":"Gene Expression Patterns"},{"issue":"6","key":"10364_CR29","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2020.04.034","volume":"181","author":"M Orthofer","year":"2020","unstructured":"Orthofer, M., Valsesia, A., M\u00e4gi, R., Wang, Q. P., Kaczanowska, J., Kozieradzki, I., et al. (2020). Identification of ALK in thinness. Cell, 181(6), 1246\u201362.e22.","journal-title":"Cell"},{"issue":"16","key":"10364_CR30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200476119","volume":"119","author":"M Ahmed","year":"2022","unstructured":"Ahmed, M., Kaur, N., Cheng, Q., Shanabrough, M., Tretiakov, E. O., Harkany, T., et al. (2022). A hypothalamic pathway for augmentor \u03b1-controlled body weight regulation. Proceedings of the National Academy of Sciences of the United States of America, 119(16), Article e2200476119.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10364_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123542","volume":"10","author":"B Witek","year":"2015","unstructured":"Witek, B., El Wakil, A., Nord, C., Ahlgren, U., Eriksson, M., Vernersson-Lindahl, E., et al. (2015). Targeted disruption of ALK reveals a potential role in hypogonadotropic hypogonadism. PLoS ONE, 10(5), Article e0123542.","journal-title":"PLoS ONE"},{"issue":"21","key":"10364_CR32","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1002\/cncr.27450","volume":"118","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt, A. J., Rothman, M. S., Salian-Mehta, S., Kiseljak-Vassiliades, K., Oton, A. B., Doebele, R. C., et al. (2012). Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer, 118(21), 5302\u20135309.","journal-title":"Cancer"},{"issue":"5151","key":"10364_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science, 263(5151), 1281\u20131284.","journal-title":"Science"},{"issue":"2","key":"10364_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/JTO.0000000000000050","volume":"9","author":"LL de Figueiredo-Pontes","year":"2014","unstructured":"de Figueiredo-Pontes, L. L., Wong, D.W.-S., Tin, V.P.-C., Chung, L.-P., Yasuda, H., Yamaguchi, N., et al. (2014). Identification and characterization of ALK kinase splicing isoforms in non\u2013small-cell lung cancer. Journal of Thoracic Oncology, 9(2), 248\u2013253.","journal-title":"Journal of Thoracic Oncology"},{"issue":"7573","key":"10364_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature15258","volume":"526","author":"T Wiesner","year":"2015","unstructured":"Wiesner, T., Lee, W., Obenauf, A. C., Ran, L., Murali, R., Zhang, Q. F., et al. (2015). Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 526(7573), 453\u2013457.","journal-title":"Nature"},{"issue":"5","key":"10364_CR36","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ajpath.2012.01.008","volume":"180","author":"D Vishwamitra","year":"2012","unstructured":"Vishwamitra, D., Li, Y., Wilson, D., Manshouri, R., Curry, C. V., Shi, B., et al. (2012). MicroRNA 96 Is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. The American Journal of Pathology., 180(5), 1772\u20131780.","journal-title":"The American Journal of Pathology."},{"issue":"34","key":"10364_CR37","doi-asserted-by":"publisher","first-page":"56518","DOI":"10.18632\/oncotarget.17033","volume":"8","author":"M De Mariano","year":"2017","unstructured":"De Mariano, M., Stigliani, S., Moretti, S., Parodi, F., Croce, M., Bernardi, C., et al. (2017). A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma. Oncotarget, 8(34), 56518\u201356532.","journal-title":"Oncotarget"},{"issue":"9","key":"10364_CR38","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-03-3531","volume":"64","author":"P Bonvini","year":"2004","unstructured":"Bonvini, P., Dalla Rosa, H., Vignes, N., & Rosolen, A. (2004). Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: Role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Research, 64(9), 3256\u20133264.","journal-title":"Cancer Research"},{"issue":"5","key":"10364_CR39","first-page":"1559","volume":"62","author":"P Bonvini","year":"2002","unstructured":"Bonvini, P., Gastaldi, T., Falini, B., & Rosolen, A. (2002). Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: Down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Research, 62(5), 1559\u20131566.","journal-title":"Cancer Research"},{"issue":"17","key":"10364_CR40","doi-asserted-by":"publisher","first-page":"6978","DOI":"10.1158\/0008-5472.CAN-10-0861","volume":"70","author":"F Lagarrigue","year":"2010","unstructured":"Lagarrigue, F., Dupuis-Coronas, S., Ramel, D., Delsol, G., Tronch\u00e8re, H., Payrastre, B., et al. (2010). Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase\u2013positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Research., 70(17), 6978\u20136987.","journal-title":"Cancer Research."},{"issue":"22","key":"10364_CR41","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/onc.2010.625","volume":"30","author":"E Normant","year":"2011","unstructured":"Normant, E., Paez, G., West, K. A., Lim, A. R., Slocum, K. L., Tunkey, C., et al. (2011). The Hsp90 inhibitor IPI-504 rapidly lowers EML4\u2013ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene, 30(22), 2581\u20136.","journal-title":"Oncogene"},{"issue":"9","key":"10364_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neo.2015.09.005","volume":"17","author":"D Vishwamitra","year":"2015","unstructured":"Vishwamitra, D., Curry, C. V., Shi, P., Alkan, S., & Amin, H. M. (2015). SUMOylation confers posttranslational stability on NPM-ALK oncogenic protein. Neoplasia, 17(9), 742\u2013754.","journal-title":"Neoplasia"},{"issue":"13","key":"10364_CR43","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.4161\/cc.6.13.4433","volume":"6","author":"M Allouche","year":"2007","unstructured":"Allouche, M. (2007). ALK is a novel dependence receptor: Potential implications in development and cancer. Cell Cycle, 6(13), 1533\u20131538.","journal-title":"Cell Cycle"},{"issue":"10","key":"10364_CR44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","volume":"13","author":"B Hallberg","year":"2013","unstructured":"Hallberg, B., & Palmer, R. H. (2013). Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer, 13(10), 685\u2013700.","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10364_CR45","first-page":"3692","volume":"9","author":"JD Khoury","year":"2003","unstructured":"Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., Yared, M. A., Tsioli, P., Leventaki, V., et al. (2003). Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK\u2212 anaplastic large cell lymphoma. Clinical cancer research., 9(10), 3692\u20133699.","journal-title":"Clinical cancer research."},{"issue":"6","key":"10364_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm1249","volume":"11","author":"R Chiarle","year":"2005","unstructured":"Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., et al. (2005). Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine, 11(6), 623\u2013629.","journal-title":"Nature Medicine"},{"issue":"7","key":"10364_CR47","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","volume":"21","author":"A Zamo","year":"2002","unstructured":"Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., et al. (2002). Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 21(7), 1038\u20131047.","journal-title":"Oncogene"},{"issue":"5","key":"10364_CR48","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","volume":"101","author":"R Chiarle","year":"2003","unstructured":"Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., et al. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 101(5), 1919\u20131927.","journal-title":"Blood"},{"issue":"7","key":"10364_CR49","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2006-04-020305","volume":"108","author":"L Qiu","year":"2006","unstructured":"Qiu, L., Lai, R., Lin, Q., Lau, E., Thomazy, D. M., Calame, D., et al. (2006). Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood, 108(7), 2407\u20132415.","journal-title":"Blood"},{"issue":"2","key":"10364_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2353\/ajpath.2009.080982","volume":"175","author":"J Dien Bard","year":"2009","unstructured":"Dien Bard, J., Gelebart, P., Anand, M., Zak, Z., Hegazy, S. A., Amin, H. M., et al. (2009). IL-21 contributes to JAK3\/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. American Journal of Pathology, 175(2), 825\u2013834.","journal-title":"American Journal of Pathology"},{"issue":"9","key":"10364_CR51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.humpath.2005.07.011","volume":"36","author":"R Lai","year":"2005","unstructured":"Lai, R., Rassidakis, G. Z., Lin, Q., Atwell, C., Medeiros, L. J., & Amin, H. M. (2005). Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Human Pathology, 36(9), 939\u2013944.","journal-title":"Human Pathology"},{"issue":"35","key":"10364_CR52","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1038\/sj.onc.1206849","volume":"22","author":"HM Amin","year":"2003","unstructured":"Amin, H. M., Medeiros, L. J., Ma, Y., Feretzaki, M., Das, P., Leventaki, V., et al. (2003). Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene, 22(35), 5399\u20135407.","journal-title":"Oncogene"},{"issue":"1","key":"10364_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2141.2006.06259.x","volume":"135","author":"X Shi","year":"2006","unstructured":"Shi, X., Franko, B., Frantz, C., Amin, H. M., & Lai, R. (2006). JSI-124 (cucurbitacin I) inhibits Janus kinase-3\/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. British Journal of Haematology, 135(1), 26\u201332.","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10364_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101472","volume":"5","author":"N Prutsch","year":"2024","unstructured":"Prutsch, N., He, S., Berezovskaya, A., Durbin, A. D., Dharia, N. V., Maher, K. A., et al. (2024). STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. Cell Reports Medicine, 5(3), Article 101472.","journal-title":"Cell Reports Medicine"},{"issue":"32","key":"10364_CR55","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1038\/sj.onc.1207703","volume":"23","author":"HM Amin","year":"2004","unstructured":"Amin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., et al. (2004). Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene, 23(32), 5426\u20135434.","journal-title":"Oncogene"},{"issue":"8","key":"10364_CR56","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ajpath.2022.05.005","volume":"192","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., Wang, H. Y., Nayak, A., Nunez-Cruz, S., Slupianek, A., Liu, X., et al. (2022). Induction of transcriptional inhibitor HES1 and the related repression of tumor-suppressor TXNIP are important components of cell-transformation program imposed by oncogenic kinase NPM-ALK. American Journal of Pathology, 192(8), 1186\u20131198.","journal-title":"American Journal of Pathology"},{"issue":"15","key":"10364_CR57","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood.2022018494","volume":"141","author":"T Brandstoetter","year":"2023","unstructured":"Brandstoetter, T., Schmoellerl, J., Grausenburger, R., Kollmann, S., Doma, E., Huuhtanen, J., et al. (2023). SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Blood, 141(15), 1831\u20131845.","journal-title":"Blood"},{"issue":"22","key":"10364_CR58","doi-asserted-by":"publisher","first-page":"8611","DOI":"10.1158\/0008-5472.CAN-09-2655","volume":"69","author":"C Ambrogio","year":"2009","unstructured":"Ambrogio, C., Martinengo, C., Voena, C., Tondat, F., Riera, L., di Celle, P. F., et al. (2009). NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Research, 69(22), 8611\u20138619.","journal-title":"Cancer Research"},{"issue":"1","key":"10364_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3324\/haematol.2013.088286","volume":"99","author":"E Spaccarotella","year":"2014","unstructured":"Spaccarotella, E., Pellegrino, E., Ferracin, M., Ferreri, C., Cuccuru, G., Liu, C., et al. (2014). STAT3-mediated activation of microRNA cluster 17\u201392 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 99(1), 116\u2013124.","journal-title":"Haematologica"},{"issue":"9","key":"10364_CR60","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1172\/JCI78488","volume":"125","author":"C Hoareau-Aveilla","year":"2015","unstructured":"Hoareau-Aveilla, C., Valentin, T., Daugrois, C., Quelen, C., Mitou, G., Quentin, S., et al. (2015). Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. Journal of Clinical Investigation., 125(9), 3505\u20133518.","journal-title":"Journal of Clinical Investigation."},{"issue":"1","key":"10364_CR61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/path.4171","volume":"230","author":"H Zhu","year":"2013","unstructured":"Zhu, H., Vishwamitra, D., Curry, C. V., Manshouri, R., Diao, L., Khan, A., et al. (2013). NPM-ALK up-regulates iNOS expression through a STAT3\/microRNA-26a-dependent mechanism. The Journal of Pathology, 230(1), 82\u201394.","journal-title":"The Journal of Pathology"},{"issue":"1","key":"10364_CR62","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12890-021-01553-z","volume":"21","author":"Y Li","year":"2021","unstructured":"Li, Y., Li, Y., Zhang, H., Shi, R., Zhang, Z., Liu, H., et al. (2021). EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. BMC Pulmonary Medicine., 21(1), 190.","journal-title":"BMC Pulmonary Medicine."},{"issue":"1","key":"10364_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00254-y","volume":"6","author":"N Yanagimura","year":"2022","unstructured":"Yanagimura, N., Takeuchi, S., Fukuda, K., Arai, S., Tanimoto, A., Nishiyama, A., et al. (2022). STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ Precision Oncology, 6(1), Article 11.","journal-title":"NPJ Precision Oncology"},{"issue":"13","key":"10364_CR64","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood.V96.13.4319","volume":"96","author":"RY Bai","year":"2000","unstructured":"Bai, R. Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C., & Duyster, J. (2000). Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway. Blood, 96(13), 4319\u20134327.","journal-title":"Blood"},{"issue":"5","key":"10364_CR65","first-page":"2194","volume":"61","author":"A Slupianek","year":"2001","unstructured":"Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., et al. (2001). Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Research, 61(5), 2194\u20132199.","journal-title":"Cancer Research"},{"issue":"5573","key":"10364_CR66","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296(5573), 1655\u20131657.","journal-title":"Science"},{"issue":"5325","key":"10364_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1126\/science.277.5325.567","volume":"277","author":"D Stokoe","year":"1997","unstructured":"Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., et al. (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science, 277(5325), 567\u2013570.","journal-title":"Science"},{"issue":"1","key":"10364_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., et al. (2023). PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer, 22(1), 138.","journal-title":"Molecular Cancer"},{"issue":"11","key":"10364_CR69","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/leu.2015.127","volume":"29","author":"V Atsaves","year":"2015","unstructured":"Atsaves, V., Zhang, R., Ruder, D., Pan, Y., Leventaki, V., Rassidakis, G. Z., et al. (2015). Constitutive control of AKT1 gene expression by JUNB\/CJUN in ALK+ anaplastic large-cell lymphoma: A novel crosstalk mechanism. Leukemia, 29(11), 2162\u20132172.","journal-title":"Leukemia"},{"issue":"38","key":"10364_CR70","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/sj.onc.1210346","volume":"26","author":"M Marzec","year":"2007","unstructured":"Marzec, M., Kasprzycka, M., Liu, X., El-Salem, M., Halasa, K., Raghunath, P. N., et al. (2007). Oncogenic tyrosine kinase NPM\/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene, 26(38), 5606\u20135614.","journal-title":"Oncogene"},{"issue":"2","key":"10364_CR71","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G., & Manning, B. D. (2020). The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism. Nature Reviews Cancer., 20(2), 74\u201388.","journal-title":"Nature Reviews Cancer."},{"issue":"5","key":"10364_CR72","first-page":"2194","volume":"61","author":"A Slupianek","year":"2001","unstructured":"Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., et al. (2001). Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer research., 61(5), 2194\u20132199.","journal-title":"Cancer research."},{"issue":"2","key":"10364_CR73","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2004-06-2125","volume":"105","author":"GZ Rassidakis","year":"2005","unstructured":"Rassidakis, G. Z., Feretzaki, M., Atwell, C., Grammatikakis, I., Lin, Q., Lai, R., et al. (2005). Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood, 105(2), 827\u2013829.","journal-title":"Blood"},{"issue":"12","key":"10364_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.exphem.2004.11.002","volume":"32","author":"A Slupianek","year":"2004","unstructured":"Slupianek, A., & Skorski, T. (2004). NPM\/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology, 32(12), 1265\u20131271.","journal-title":"Experimental Hematology"},{"issue":"12","key":"10364_CR75","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1182\/blood-2003-03-0820","volume":"103","author":"TL Gu","year":"2004","unstructured":"Gu, T. L., Tothova, Z., Scheijen, B., Griffin, J. D., Gilliland, D. G., & Sternberg, D. W. (2004). NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood, 103(12), 4622\u20134629.","journal-title":"Blood"},{"issue":"5","key":"10364_CR76","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/1878-0261.13342","volume":"17","author":"SS Talwelkar","year":"2023","unstructured":"Talwelkar, S. S., M\u00e4yr\u00e4np\u00e4\u00e4, M. I., Sch\u00fcler, J., Linnavirta, N., Hemmes, A., Adinolfi, S., et al. (2023). PI3K\u03b2 inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. Molecular Oncology, 17(5), 747\u2013764.","journal-title":"Molecular Oncology"},{"issue":"18","key":"10364_CR77","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.18632\/oncotarget.2372","volume":"5","author":"NF Moore","year":"2014","unstructured":"Moore, N. F., Azarova, A. M., Bhatnagar, N., Ross, K. N., Drake, L. E., Frumm, S., et al. (2014). Molecular rationale for the use of PI3K\/AKT\/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget, 5(18), 8737\u20138749.","journal-title":"Oncotarget"},{"key":"10364_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174252","author":"J Guan","year":"2023","unstructured":"Guan, J., Boren\u00e4s, M., Xiong, J., Lai, W. Y., Palmer, R. H., & Hallberg, B. (2023). IGF1R contributes to cell proliferation in ALK-mutated neuroblastoma with preference for activating the PI3K-AKT signaling pathway. Cancers. https:\/\/doi.org\/10.3390\/cancers15174252","journal-title":"Cancers"},{"issue":"6","key":"10364_CR79","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.onc.1209843","volume":"26","author":"M Marzec","year":"2007","unstructured":"Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P. N., Wlodarski, P., & Wasik, M. A. (2007). Oncogenic tyrosine kinase NPM\/ALK induces activation of the MEK\/ERK signaling pathway independently of c-Raf. Oncogene, 26(6), 813\u2013821.","journal-title":"Oncogene"},{"issue":"4","key":"10364_CR80","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cellsig.2006.09.007","volume":"19","author":"SD Turner","year":"2007","unstructured":"Turner, S. D., Yeung, D., Hadfield, K., Cook, S. J., & Alexander, D. R. (2007). The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cellular Signalling, 19(4), 740\u2013747.","journal-title":"Cellular Signalling"},{"issue":"9","key":"10364_CR81","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1182\/blood-2007-02-071258","volume":"110","author":"PB Staber","year":"2007","unstructured":"Staber, P. B., Vesely, P., Haq, N., Ott, R. G., Funato, K., Bambach, I., et al. (2007). The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling. Blood, 110(9), 3374\u20133383.","journal-title":"Blood"},{"issue":"9","key":"10364_CR82","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/nm.3930","volume":"21","author":"G Hrustanovic","year":"2015","unstructured":"Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., et al. (2015). RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK\u2013positive lung cancer. Nature Medicine, 21(9), 1038\u20131047.","journal-title":"Nature Medicine"},{"issue":"46","key":"10364_CR83","doi-asserted-by":"publisher","first-page":"75968","DOI":"10.18632\/oncotarget.12513","volume":"7","author":"K Chen","year":"2016","unstructured":"Chen, K., Lv, F., Xu, G., Zhang, M., Wu, Y., & Wu, Z. (2016). Phosphoproteomics reveals ALK promote cell progress via RAS\/ JNK pathway in neuroblastoma. Oncotarget, 7(46), 75968\u201380.","journal-title":"Oncotarget"},{"issue":"12","key":"10364_CR84","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1128\/MCB.18.12.6951","volume":"18","author":"R-Y Bai","year":"1998","unstructured":"Bai, R.-Y., Dieter, P., Peschel, C., Morris, S. W., & Duyster, J. (1998). Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-\u03b3 to mediate its mitogenicity. Molecular and cellular biology., 18(12), 6951\u20136961.","journal-title":"Molecular and cellular biology."},{"issue":"5992","key":"10364_CR85","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/312315a0","volume":"312","author":"MJ Berridge","year":"1984","unstructured":"Berridge, M. J., & Irvine, R. F. (1984). Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature, 312(5992), 315\u2013321.","journal-title":"Nature"},{"issue":"5961","key":"10364_CR86","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/308693a0","volume":"308","author":"Y Nishizuka","year":"1984","unstructured":"Nishizuka, Y. (1984). The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature, 308(5961), 693\u2013698.","journal-title":"Nature"},{"key":"10364_CR87","doi-asserted-by":"crossref","unstructured":"Prutsch N., He S., Berezovskaya A., Durbin A. D., Dharia N. V., & Maher K. A., et al. (2024) STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuity of anaplastic large cell lymphoma. Cell Reports Medecine, 5(3), 101472.","DOI":"10.1016\/j.xcrm.2024.101472"},{"issue":"10","key":"10364_CR88","doi-asserted-by":"publisher","first-page":"8823","DOI":"10.18632\/oncotarget.24260","volume":"9","author":"AB Pilling","year":"2018","unstructured":"Pilling, A. B., Kim, J., Estrada-Bernal, A., Zhou, Q., Le, A. T., Singleton, K. R., et al. (2018). ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget, 9(10), 8823\u20138835.","journal-title":"Oncotarget"},{"key":"10364_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814337","author":"C Shang","year":"2023","unstructured":"Shang, C., Lai, J., Haque, M., Chen, W., Wang, P., & Lai, R. (2023). Nuclear NPM-ALK protects Myc from proteasomal degradation and contributes to its high expression in cancer stem-like cells in ALK-positive anaplastic large cell lymphoma. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms241814337","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10364_CR90","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno, K., Chalmers, Z. R., Pamarthy, S., Vatapalli, R., Rodriguez, Y., Lysy, B., et al. (2021). Activated ALK cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer. Cancer Research, 81(8), 2157\u20132170.","journal-title":"Cancer Research"},{"issue":"2","key":"10364_CR91","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2007-11-125658","volume":"114","author":"P Shi","year":"2009","unstructured":"Shi, P., Lai, R., Lin, Q., Iqbal, A. S., Young, L. C., Kwak, L. W., et al. (2009). IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood, 114(2), 360\u2013370.","journal-title":"Blood"},{"key":"10364_CR92","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-015-0324-2","volume":"14","author":"D Vishwamitra","year":"2015","unstructured":"Vishwamitra, D., Curry, C. V., Alkan, S., Song, Y. H., Gallick, G. E., Kaseb, A. O., et al. (2015). The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK\u207a T-cell lymphoma. Molecular Cancer, 14, 53.","journal-title":"Molecular Cancer"},{"issue":"6","key":"10364_CR93","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1593\/neo.122012","volume":"15","author":"B Shi","year":"2013","unstructured":"Shi, B., Vishwamitra, D., Granda, J. G., Whitton, T., Shi, P., & Amin, H. M. (2013). Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia, 15(6), 669\u2013683.","journal-title":"Neoplasia"},{"issue":"1","key":"10364_CR94","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-019-0768-8","volume":"12","author":"B George","year":"2019","unstructured":"George, B., George, S. K., Shi, W., Haque, A., Shi, P., Eskandari, G., et al. (2019). Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma. Journal of Hematology & Oncology, 12(1), 80.","journal-title":"Journal of Hematology & Oncology"},{"issue":"9","key":"10364_CR95","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm.3667","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., et al. (2014). Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature Medicine, 20(9), 1027\u20131034.","journal-title":"Nature Medicine"},{"issue":"2","key":"10364_CR96","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/1078-0432.CCR-10-0434","volume":"17","author":"HE Metz","year":"2011","unstructured":"Metz, H. E., & Houghton, A. M. (2011). Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clinical Cancer Research, 17(2), 206\u2013211.","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10364_CR97","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1073\/pnas.93.9.4181","volume":"93","author":"J Fujimoto","year":"1996","unstructured":"Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., et al. (1996). Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A., 93(9), 4181\u20134186.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"12","key":"10364_CR98","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41419-024-07272-7","volume":"15","author":"J Sampson","year":"2024","unstructured":"Sampson, J., Ju, H. M., Zhang, N., Yeoh, S., Choi, J., & Bayliss, R. (2024). Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer. Cell Death & Disease, 15(12), 912.","journal-title":"Cell Death & Disease"},{"issue":"4","key":"10364_CR99","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1523\/JNEUROSCI.15-04-02888.1995","volume":"15","author":"Y Li","year":"1995","unstructured":"Li, Y., Holtzman, D. M., Kromer, L. F., Kaplan, D. R., Chua-Couzens, J., Clary, D. O., et al. (1995). Regulation of TrkA and ChAT expression in developing rat basal forebrain: Evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. Journal of Neuroscience, 15(4), 2888\u20132905.","journal-title":"Journal of Neuroscience"},{"issue":"6320","key":"10364_CR100","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/350678a0","volume":"350","author":"BL Hempstead","year":"1991","unstructured":"Hempstead, B. L., Martin-Zanca, D., Kaplan, D. R., Parada, L. F., & Chao, M. V. (1991). High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature, 350(6320), 678\u2013683.","journal-title":"Nature"},{"issue":"6","key":"10364_CR101","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/0896-6273(92)90066-M","volume":"9","author":"S Jing","year":"1992","unstructured":"Jing, S., Tapley, P., & Barbacid, M. (1992). Nerve growth factor mediates signal transduction through trk homodimer receptors. Neuron, 9(6), 1067\u20131079.","journal-title":"Neuron"},{"issue":"9","key":"10364_CR102","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/1878-0261.12088","volume":"11","author":"W Shi","year":"2017","unstructured":"Shi, W., George, S. K., George, B., Curry, C. V., Murzabdillaeva, A., Alkan, S., et al. (2017). TrkA is a binding partner of NPM-ALK that promotes the survival of ALK(+) T-cell lymphoma. Molecular Oncology, 11(9), 1189\u20131207.","journal-title":"Molecular Oncology"},{"issue":"11","key":"10364_CR103","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/nm.2966","volume":"18","author":"D Laimer","year":"2012","unstructured":"Laimer, D., Dolznig, H., Kollmann, K., Vesely, P. W., Schlederer, M., Merkel, O., et al. (2012). PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Medicine, 18(11), 1699\u20131704.","journal-title":"Nature Medicine"},{"issue":"6","key":"10364_CR104","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/S0002-9440(10)63781-9","volume":"164","author":"R Lai","year":"2004","unstructured":"Lai, R., Rassidakis, G. Z., Medeiros, L. J., Ramdas, L., Goy, A. H., Cutler, C., et al. (2004). Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. American Journal of Pathology, 164(6), 2251\u20132258.","journal-title":"American Journal of Pathology"},{"issue":"6","key":"10364_CR105","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/pin.12796","volume":"69","author":"K Yorita","year":"2019","unstructured":"Yorita, K., Togashi, Y., Nakagawa, H., Miyazaki, K., Sakata, S., Baba, S., et al. (2019). Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall. Pathology International, 69(6), 366\u2013371.","journal-title":"Pathology International"},{"issue":"5","key":"10364_CR106","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-022-03389-2","volume":"481","author":"N Klub\u00ed\u010dkov\u00e1","year":"2022","unstructured":"Klub\u00ed\u010dkov\u00e1, N., Michal, M., Agaimy, A., Zidar, N., Pavlovsk\u00fd, M., Yorita, K., et al. (2022). TIMP3: : ALK fusions characterize a distinctive myxoid fibroblastic tumor of the vocal cords: A report of 7 cases. Virchows Archiv, 481(5), 721\u2013729.","journal-title":"Virchows Archiv"},{"issue":"7","key":"10364_CR107","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0000000000001481","volume":"44","author":"KA Devereaux","year":"2020","unstructured":"Devereaux, K. A., Fitzpatrick, M. B., Hartinger, S., Jones, C., Kunder, C. A., & Longacre, T. A. (2020). Pregnancy-associated inflammatory myofibroblastic tumors of the uterus are clinically distinct and highly enriched for TIMP3-ALK and THBS1-ALK fusions. American Journal of Surgical Pathology, 44(7), 970\u2013981.","journal-title":"American Journal of Surgical Pathology"},{"issue":"3","key":"10364_CR108","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/his.14833","volume":"82","author":"FL Duan","year":"2023","unstructured":"Duan, F. L., Yang, H., Gong, X., Zuo, Z., Qin, S., Ji, J., et al. (2023). Clinicopathological features of rhabdomyosarcoma with novel FET: : TFCP2 and TIMP3: : ALK fusion: Report of two cases and literature review. Histopathology, 82(3), 478\u2013484.","journal-title":"Histopathology"},{"issue":"10","key":"10364_CR109","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/neuonc\/nov039","volume":"17","author":"TK Olsen","year":"2015","unstructured":"Olsen, T. K., Panagopoulos, I., Meling, T. R., Micci, F., Gorunova, L., Thorsen, J., et al. (2015). Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? Neuro-Oncology., 17(10), 1365\u20131373.","journal-title":"Neuro-Oncology."},{"issue":"7","key":"10364_CR110","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","volume":"10","author":"M Clarke","year":"2020","unstructured":"Clarke, M., Mackay, A., Ismer, B., Pickles, J. C., Tatevossian, R. G., Newman, S., et al. (2020). Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discovery, 10(7), 942\u201363.","journal-title":"Cancer Discovery"},{"key":"10364_CR111","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cancergen.2020.12.005","volume":"252\u2013253","author":"Y Zhong","year":"2021","unstructured":"Zhong, Y., Lin, F., Xu, F., Schubert, J., Wu, J., Wainwright, L., et al. (2021). Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma. Cancer Genetics, 252\u2013253, 37\u201342.","journal-title":"Cancer Genetics"},{"issue":"11","key":"10364_CR112","doi-asserted-by":"publisher","first-page":"E2457","DOI":"10.1210\/jc.2014-2611","volume":"99","author":"DG McFadden","year":"2014","unstructured":"McFadden, D. G., Dias-Santagata, D., Sadow, P. M., Lynch, K. D., Lubitz, C., Donovan, S. E., et al. (2014). Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism, 99(11), E2457\u2013E62.","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10364_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087170","volume":"9","author":"G P\u00e9rot","year":"2014","unstructured":"P\u00e9rot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., et al. (2014). Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas. PLoS ONE, 9(1), Article e87170.","journal-title":"PLoS ONE"},{"issue":"8","key":"10364_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005467","volume":"11","author":"JH Ji","year":"2015","unstructured":"Ji, J. H., Oh, Y. L., Hong, M., Yun, J. W., Lee, H.-W., Kim, D., et al. (2015). Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genetics, 11(8), Article e1005467.","journal-title":"PLoS Genetics"},{"issue":"2","key":"10364_CR115","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12022-024-09808-1","volume":"35","author":"KP Shih","year":"2024","unstructured":"Shih, K. P., Lee, Y. C., Tsai, J. J., Lin, S. H., Liu, C. Y., Li, W. S., et al. (2024). Clinicopathologic features and cytologic correlation of ALK-rearranged papillary thyroid carcinoma: A series of eight cases. Endocrine Pathology, 35(2), 134\u2013146.","journal-title":"Endocrine Pathology"},{"issue":"7153","key":"10364_CR116","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561\u2013566.","journal-title":"Nature"},{"issue":"1","key":"10364_CR117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., et al. (2008). EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. Journal of thoracic oncology., 3(1), 13\u201317.","journal-title":"Journal of thoracic oncology."},{"issue":"12","key":"10364_CR118","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1002\/cncr.25843","volume":"117","author":"DWS Wong","year":"2011","unstructured":"Wong, D. W. S., Leung, E. L. H., Wong, S. K. M., Tin, V. P. C., Sihoe, A. D. L., Cheng, L. C., et al. (2011). A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer, 117(12), 2709\u20132718.","journal-title":"Cancer"},{"issue":"6","key":"10364_CR119","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/gcc.21945","volume":"51","author":"Y Jung","year":"2012","unstructured":"Jung, Y., Kim, P., Jung, Y., Keum, J., Kim, S. N., Choi, Y. S., et al. (2012). Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes, Chromosomes & Cancer, 51(6), 590\u2013597.","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"2","key":"10364_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031323","volume":"7","author":"Y Togashi","year":"2012","unstructured":"Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., et al. (2012). KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE, 7(2), Article e31323.","journal-title":"PLoS ONE"},{"issue":"4","key":"10364_CR121","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/JTO.0000000000000093","volume":"9","author":"YL Choi","year":"2014","unstructured":"Choi, Y. L., Lira, M. E., Hong, M., Kim, R. N., Choi, S. J., Song, J. Y., et al. (2014). A novel fusion of TPR and ALK in lung adenocarcinoma. Journal of Thoracic Oncology, 9(4), 563\u2013566.","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10364_CR122","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2015.03.028","volume":"362","author":"AG Iyevleva","year":"2015","unstructured":"Iyevleva, A. G., Raskin, G. A., Tiurin, V. I., Sokolenko, A. P., Mitiushkina, N. V., Aleksakhina, S. N., et al. (2015). Novel ALK fusion partners in lung cancer. Cancer Letters, 362(1), 116\u2013121.","journal-title":"Cancer Letters"},{"issue":"12","key":"10364_CR123","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/j.jtho.2017.08.009","volume":"12","author":"Y Nakanishi","year":"2017","unstructured":"Nakanishi, Y., Masuda, S., Iida, Y., Takahashi, N., & Hashimoto, S. (2017). Case report of non-small cell lung cancer with STRN-ALK translocation: A nonresponder to alectinib. Journal of Thoracic Oncology, 12(12), e202\u2013e204.","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10364_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12679-8","volume":"7","author":"JA Vendrell","year":"2017","unstructured":"Vendrell, J. A., Taviaux, S., B\u00e9ganton, B., Godreuil, S., Audran, P., Grand, D., et al. (2017). Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Scientific Reports, 7(1), Article 12510.","journal-title":"Scientific Reports"},{"issue":"4","key":"10364_CR125","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du, X., Shao, Y., Qin, H. F., Tai, Y. H., & Gao, H. J. (2018). ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer., 9(4), 423\u2013430.","journal-title":"Thorac Cancer."},{"key":"10364_CR126","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2019.08.032","volume":"137","author":"T Feng","year":"2019","unstructured":"Feng, T., Chen, Z., Gu, J., Wang, Y., Zhang, J., & Min, L. (2019). The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. Lung Cancer, 137, 19\u201322.","journal-title":"Lung Cancer"},{"issue":"12","key":"10364_CR127","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.21037\/tlcr-23-656","volume":"12","author":"H Li","year":"2023","unstructured":"Li, H., Liu, J., Lan, S., Zhong, R., Cui, Y., Christopoulos, P., et al. (2023). An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: A case report. Transl Lung Cancer Res., 12(12), 2538\u20132549.","journal-title":"Transl Lung Cancer Res."},{"issue":"9","key":"10364_CR128","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","volume":"7","author":"E Lin","year":"2009","unstructured":"Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., et al. (2009). Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non\u2013small cell lung cancers. Molecular Cancer Research., 7(9), 1466\u20131476.","journal-title":"Molecular Cancer Research."},{"issue":"44","key":"10364_CR129","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.3748\/wjg.v12.i44.7104","volume":"12","author":"FR Jazii","year":"2006","unstructured":"Jazii, F. R., Najafi, Z., Malekzadeh, R., Conrads, T. P., Ziaee, A. A., Abnet, C., et al. (2006). Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World Journal of Gastroenterology, 12(44), 7104\u20137112.","journal-title":"World Journal of Gastroenterology"},{"key":"10364_CR130","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00109-007-0159-4","volume":"85","author":"X-L Du","year":"2007","unstructured":"Du, X.-L., Hu, H., Lin, D.-C., Xia, S.-H., Shen, X.-M., Zhang, Y., et al. (2007). Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. Journal of molecular medicine., 85, 863\u2013875.","journal-title":"Journal of molecular medicine."},{"key":"10364_CR131","doi-asserted-by":"publisher","first-page":"1686666","DOI":"10.3389\/fimmu.2025.1686666","volume":"16","author":"H Wang","year":"2025","unstructured":"Wang, H., You, L., Pan, H., Qiu, X., & Sheng, J. (2025). Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1-ALK fusion: A case report and review. Frontiers in Immunology, 16, 1686666.","journal-title":"Frontiers in Immunology"},{"key":"10364_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645370","volume":"11","author":"Z Wen","year":"2021","unstructured":"Wen, Z., Xiong, D., Zhang, S., Liu, J., Li, B., Li, R., et al. (2021). Case report: RAB10-ALK: A novel ALK fusion in a patient with gastric cancer. Frontiers in Oncology, 11, Article 645370.","journal-title":"Frontiers in Oncology"},{"key":"10364_CR133","doi-asserted-by":"publisher","DOI":"10.1200\/po.19.00365","author":"A Gower","year":"2020","unstructured":"Gower, A., Golestany, B., Gong, J., Singhi, A. D., & Hendifar, A. E. (2020). Novel ALK fusion, PPFIBP1-ALK, in pancreatic ductal adenocarcinoma responsive to alectinib and lorlatinib. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/po.19.00365","journal-title":"JCO Precision Oncology"},{"key":"10364_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.724815","volume":"11","author":"K Ou","year":"2021","unstructured":"Ou, K., Liu, X., Li, W., Yang, Y., Ying, J., & Yang, L. (2021). ALK rearrangement-positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: A case report. Frontiers in Oncology, 11, Article 724815.","journal-title":"Frontiers in Oncology"},{"key":"10364_CR135","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejim.2019.10.030","volume":"71","author":"D Trombetta","year":"2020","unstructured":"Trombetta, D., Parente, P., Latiano, T. P., Fabrizio, F. P., & Muscarella, L. A. (2020). Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma. European Journal of Internal Medicine, 71, 92\u201394.","journal-title":"European Journal of Internal Medicine"},{"issue":"9","key":"10364_CR136","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/pin.13138","volume":"71","author":"L Favre","year":"2021","unstructured":"Favre, L., Pujals, A., Maille, P., Poullot, E., & Calderaro, J. (2021). Identification of an EML4-ALK rearrangement in an intrahepatic cholangiocarcinoma. Pathology International, 71(9), 630\u2013632.","journal-title":"Pathology International"},{"key":"10364_CR137","doi-asserted-by":"publisher","first-page":"1191646","DOI":"10.3389\/fonc.2023.1191646","volume":"13","author":"S Huang","year":"2023","unstructured":"Huang, S., Li, D., Huang, Y., Lu, G., Tian, Y., Zhong, X., et al. (2023). An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: A case report. Frontiers in Oncology, 13, 1191646.","journal-title":"Frontiers in Oncology"},{"issue":"12","key":"10364_CR138","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/bjc.2015.401","volume":"113","author":"A Amatu","year":"2015","unstructured":"Amatu, A., Somaschini, A., Cerea, G., Bosotti, R., Valtorta, E., Buonandi, P., et al. (2015). Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British Journal of Cancer, 113(12), 1730\u20131734.","journal-title":"British Journal of Cancer"},{"issue":"15","key":"10364_CR139","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-15-3000","volume":"22","author":"E Yakirevich","year":"2016","unstructured":"Yakirevich, E., Resnick, M. B., Mangray, S., Wheeler, M., Jackson, C. L., Lombardo, K. A., et al. (2016). Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clinical Cancer Research., 22(15), 3831\u20133840.","journal-title":"Clinical Cancer Research."},{"issue":"1","key":"10364_CR140","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000511069","volume":"14","author":"S-Y Hsiao","year":"2021","unstructured":"Hsiao, S.-Y., He, H.-L., Weng, T.-S., Lin, C.-Y., Chao, C.-M., Huang, W.-T., et al. (2021). Colorectal cancer with EML4-ALK fusion gene response to alectinib: A case report and review of the literature. Case Reports in Oncology., 14(1), 232\u2013238.","journal-title":"Case Reports in Oncology."},{"key":"10364_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713610","author":"RS Mulkidjan","year":"2023","unstructured":"Mulkidjan, R. S., Saitova, E. S., Preobrazhenskaya, E. V., Asadulaeva, K. A., Bubnov, M. G., Otradnova, E. A., et al. (2023). ALK, ROS1, RET and NTRK1-3 gene fusions in colorectal and non-colorectal microsatellite-unstable cancers. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms241713610","journal-title":"International Journal of Molecular Sciences"},{"issue":"18","key":"10364_CR142","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1002\/cncr.27391","volume":"118","author":"E Sugawara","year":"2012","unstructured":"Sugawara, E., Togashi, Y., Kuroda, N., Sakata, S., Hatano, S., Asaka, R., et al. (2012). Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer, 118(18), 4427\u20134436.","journal-title":"Cancer"},{"issue":"6","key":"10364_CR143","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/PAS.0000000000000179","volume":"38","author":"NE Smith","year":"2014","unstructured":"Smith, N. E., Deyrup, A. T., Mari\u00f1o-Enriquez, A., Fletcher, J. A., Bridge, J. A., Illei, P. B., et al. (2014). VCL-ALK renal cell carcinoma in children with sickle-cell trait: The eighth sickle-cell nephropathy? American Journal of Surgical Pathology, 38(6), 858\u2013863.","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"10364_CR144","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/PAS.0000000000000610","volume":"40","author":"H Kusano","year":"2016","unstructured":"Kusano, H., Togashi, Y., Akiba, J., Moriya, F., Baba, K., Matsuzaki, N., et al. (2016). Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene. The American journal of surgical pathology., 40(6), 761\u2013769.","journal-title":"The American journal of surgical pathology."},{"issue":"2","key":"10364_CR145","first-page":"2020","volume":"17","author":"Z Cao","year":"2019","unstructured":"Cao, Z., Gao, Q., Fu, M., Ni, N., Pei, Y., & Ou, W.-B. (2019). Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives. Oncology Letters., 17(2), 2020\u20132030.","journal-title":"Oncology Letters."},{"issue":"6","key":"10364_CR146","first-page":"1567","volume":"9","author":"M Shiota","year":"1994","unstructured":"Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T., & Mori, S. (1994). Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene, 9(6), 1567\u20131574.","journal-title":"Oncogene"},{"issue":"9","key":"10364_CR147","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood.V93.9.3088.409k30_3088_3095","volume":"93","author":"L Lamant","year":"1999","unstructured":"Lamant, L., Dastugue, N., Pulford, K., Delsol, G., & Mariam\u00e9, B. (1999). A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood, 93(9), 3088\u20133095.","journal-title":"Blood"},{"issue":"9","key":"10364_CR148","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood.V94.9.3265","volume":"94","author":"L Hern\u00e1ndez","year":"1999","unstructured":"Hern\u00e1ndez, L., Pinyol, M., Hern\u00e1ndez, S., Be\u00e0, S., Pulford, K., Rosenwald, A., et al. (1999). TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood, 94(9), 3265\u20133268.","journal-title":"Blood"},{"issue":"10","key":"10364_CR149","first-page":"3614","volume":"94","author":"R Siebert","year":"1999","unstructured":"Siebert, R., Gesk, S., Harder, L., Steinemann, D., Grote, W., Schlegelberger, B., et al. (1999). Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood, 94(10), 3614\u20133617.","journal-title":"Blood"},{"issue":"6","key":"10364_CR150","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood.V95.6.2144","volume":"95","author":"Z Ma","year":"2000","unstructured":"Ma, Z., Cools, J., Marynen, P., Cui, X., Siebert, R., Gesk, S., et al. (2000). Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood, 95(6), 2144\u20132149.","journal-title":"Blood"},{"issue":"10","key":"10364_CR151","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood.V95.10.3204","volume":"95","author":"C Touriol","year":"2000","unstructured":"Touriol, C., Greenland, C., Lamant, L., Pulford, K., Bernard, F., Rousset, T., et al. (2000). Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 95(10), 3204\u20133207.","journal-title":"Blood"},{"issue":"3","key":"10364_CR152","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/labinvest.3780249","volume":"81","author":"F Tort","year":"2001","unstructured":"Tort, F., Pinyol, M., Pulford, K., Roncador, G., Hernandez, L., Nayach, I., et al. (2001). Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Laboratory Investigation, 81(3), 419\u2013426.","journal-title":"Laboratory Investigation"},{"issue":"4","key":"10364_CR153","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/gcc.10033","volume":"34","author":"J Cools","year":"2002","unstructured":"Cools, J., Wlodarska, I., Somers, R., Mentens, N., Pedeutour, F., Maes, B., et al. (2002). Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes, Chromosomes & Cancer, 34(4), 354\u2013362.","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"4","key":"10364_CR154","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/gcc.10232","volume":"37","author":"L Lamant","year":"2003","unstructured":"Lamant, L., Gascoyne, R. D., Duplantier, M. M., Armstrong, F., Raghab, A., Chhanabhai, M., et al. (2003). Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. Genes, Chromosomes & Cancer, 37(4), 427\u201332.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10364_CR155","doi-asserted-by":"crossref","unstructured":"Tabb\u00f3 F, Barreca A, Piva R, Inghirami G, Group ET-CLS, (2012). ALK signaling and target therapy in anaplastic large cell lymphoma. Frontiers in Oncology, 2,\u00a041.","DOI":"10.3389\/fonc.2012.00041"},{"issue":"1","key":"10364_CR156","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/1346-8138.16981","volume":"51","author":"Y Norimatsu","year":"2024","unstructured":"Norimatsu, Y., Akatsuka, T., Matsuoka, A., Hamada, T., Mori, I., Shiomi, T., et al. (2024). Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node. The Journal of Dermatology., 51(1), 120\u2013124.","journal-title":"The Journal of Dermatology."},{"issue":"7","key":"10364_CR157","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood-2003-04-1095","volume":"102","author":"M Onciu","year":"2003","unstructured":"Onciu, M., Behm, F. G., Downing, J. R., Shurtleff, S. A., Raimondi, S. C., Ma, Z., et al. (2003). ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: Report of 2 cases. Blood, 102(7), 2642\u20134.","journal-title":"Blood"},{"issue":"2","key":"10364_CR158","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3324\/haematol.2010.031484","volume":"96","author":"C Bedwell","year":"2011","unstructured":"Bedwell, C., Rowe, D., Moulton, D., Jones, G., Bown, N., & Bacon, C. M. (2011). Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Haematologica, 96(2), 343\u2013346.","journal-title":"Haematologica"},{"issue":"3","key":"10364_CR159","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3324\/haematol.2010.033514","volume":"96","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi, K., Soda, M., Togashi, Y., Ota, Y., Sekiguchi, Y., Hatano, S., et al. (2011). Identification of a novel fusion, SQSTM1-ALK, ALK-positive large B-cell lymphoma. Haematologica, 96(3), 464\u2013467.","journal-title":"Haematologica"},{"issue":"5","key":"10364_CR160","first-page":"6977","volume":"8","author":"J Li","year":"2015","unstructured":"Li, J., Ouyang, J., Zhou, R., Chen, B., & Xu, Y. (2015). Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: Case report and review of literature. International Journal of Clinical and Experimental Medicine, 8(5), 6977\u20136985.","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"10364_CR161","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12185-016-1934-1","volume":"103","author":"K Sakamoto","year":"2016","unstructured":"Sakamoto, K., Nakasone, H., Togashi, Y., Sakata, S., Tsuyama, N., Baba, S., et al. (2016). ALK-positive large B-cell lymphoma: Identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. International journal of hematology., 103, 399\u2013408.","journal-title":"International journal of hematology."},{"issue":"8","key":"10364_CR162","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/PAS.0000000000002069","volume":"47","author":"JJ Fu","year":"2023","unstructured":"Fu, J. J., Seth, A., Ali, N., Chandar, A., & Bains, A. (2023). ALK-positive large B-Cell lymphoma with multiple epithelial antigen expression and PABPC1::ALK fusion\u202f: A novel molecular alteration. American Journal of Surgical Pathology, 47(8), 950\u2013954.","journal-title":"American Journal of Surgical Pathology"},{"key":"10364_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1174606","volume":"13","author":"A Xiao","year":"2023","unstructured":"Xiao, A., Shahmarvand, N., Nagy, A., Kumar, J., Van Ziffle, J., Devine, P., et al. (2023). TFG: : ALK fusion in ALK positive large B-cell lymphoma: A case report and review of literature. Frontiers in Oncology, 13, Article 1174606.","journal-title":"Frontiers in Oncology"},{"key":"10364_CR164","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12185-013-1482-x","volume":"99","author":"Y Maesako","year":"2014","unstructured":"Maesako, Y., Izumi, K., Okamori, S., Takeoka, K., Kishimori, C., Okumura, A., et al. (2014). inv (2)(p23q13)\/RAN-binding protein 2 (RANBP2)\u2013ALK fusion gene in myeloid leukemia that developed in an elderly woman. International journal of hematology., 99, 202\u2013207.","journal-title":"International journal of hematology."},{"issue":"13","key":"10364_CR165","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1158\/0008-5472.CAN-11-3931","volume":"72","author":"H Ren","year":"2012","unstructured":"Ren, H., Tan, Z.-P., Zhu, X., Crosby, K., Haack, H., Ren, J.-M., et al. (2012). Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer research., 72(13), 3312\u20133323.","journal-title":"Cancer research."},{"issue":"1","key":"10364_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.70043","volume":"13","author":"Q Li","year":"2025","unstructured":"Li, Q., Cai, T., Zheng, X., Zhang, S., Li, C., Tang, H., et al. (2025). EML4-ALK-positive ovarian cancer with intracranial metastasis responds to lorlatinib: A case report and literature review. Clin Case Rep., 13(1), Article e70043.","journal-title":"Clin Case Rep."},{"issue":"10","key":"10364_CR167","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1097\/PAS.0000000000001120","volume":"42","author":"N Mohammad","year":"2018","unstructured":"Mohammad, N., Haimes, J. D., Mishkin, S., Kudlow, B. A., Leong, M. Y., Chew, S. H., et al. (2018). ALK is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus. American Journal of Surgical Pathology, 42(10), 1353\u20131359.","journal-title":"American Journal of Surgical Pathology"},{"issue":"8","key":"10364_CR168","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41419-021-04065-0","volume":"12","author":"B Lu","year":"2021","unstructured":"Lu, B., Jiang, R., Xie, B., Wu, W., & Zhao, Y. (2021). Fusion genes in gynecologic tumors: The occurrence, molecular mechanism and prospect for therapy. Cell Death & Disease, 12(8), 783.","journal-title":"Cell Death & Disease"},{"issue":"2","key":"10364_CR169","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","volume":"157","author":"B Lawrence","year":"2000","unstructured":"Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., et al. (2000). TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. The American journal of pathology., 157(2), 377\u2013384.","journal-title":"The American journal of pathology."},{"issue":"2","key":"10364_CR170","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/gcc.10267","volume":"38","author":"M Debiec-Rychter","year":"2003","unstructured":"Debiec-Rychter, M., Marynen, P., Hagemeijer, A., & Pauwels, P. (2003). ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes, Chromosomes and Cancer., 38(2), 187\u2013190.","journal-title":"Genes, Chromosomes and Cancer."},{"issue":"5","key":"10364_CR171","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/ijc.21490","volume":"118","author":"I Panagopoulos","year":"2006","unstructured":"Panagopoulos, I., Nilsson, T., Domanski, H. A., Isaksson, M., Lindblom, P., Mertens, F., et al. (2006). Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. International Journal of Cancer, 118(5), 1181\u20131186.","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10364_CR172","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","volume":"35","author":"A Mari\u00f1o-Enr\u00edquez","year":"2011","unstructured":"Mari\u00f1o-Enr\u00edquez, A., Wang, W.-L., Roy, A., Lopez-Terrada, D., Lazar, A. J., Fletcher, C. D., et al. (2011). Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. The American journal of surgical pathology., 35(1), 135\u2013144.","journal-title":"The American journal of surgical pathology."},{"issue":"10","key":"10364_CR173","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-11-0063","volume":"17","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi, K., Soda, M., Togashi, Y., Sugawara, E., Hatano, S., Asaka, R., et al. (2011). Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: Reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clinical Cancer Research, 17(10), 3341\u20133348.","journal-title":"Clinical Cancer Research"},{"key":"10364_CR174","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.humpath.2017.06.013","volume":"66","author":"M Tanaka","year":"2017","unstructured":"Tanaka, M., Kohashi, K., Kushitani, K., Yoshida, M., Kurihara, S., Kawashima, M., et al. (2017). Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: Report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions. Human Pathology., 66, 177\u2013182.","journal-title":"Human Pathology."},{"issue":"12","key":"10364_CR175","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/PAS.0000000000001735","volume":"45","author":"DA Kerr","year":"2021","unstructured":"Kerr, D. A., Thompson, L. D. R., Tafe, L. J., Jo, V. Y., Neyaz, A., Divakar, P., et al. (2021). Clinicopathologic and genomic characterization of inflammatory myofibroblastic tumors of the head and neck: Highlighting a novel fusion and potential diagnostic pitfall. American Journal of Surgical Pathology, 45(12), 1707\u20131719.","journal-title":"American Journal of Surgical Pathology"},{"issue":"9","key":"10364_CR176","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/cup.14261","volume":"49","author":"KJ McCollum","year":"2022","unstructured":"McCollum, K. J., Jour, G., & Al-Rohil, R. N. (2022). Cutaneous inflammatory myofibroblastic tumor with CARS-ALK fusion: Case report and literature review. Journal of Cutaneous Pathology, 49(9), 795\u2013801.","journal-title":"Journal of Cutaneous Pathology"},{"issue":"5","key":"10364_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.70055","volume":"64","author":"D Maharjan","year":"2025","unstructured":"Maharjan, D., Dehner, C., Alani, A., Bell, R., & Segura, S. (2025). Epithelioid inflammatory myofibroblastic sarcoma: Case series with a first report of CLTC: : ALK fusion in an aggressive disease. Genes, Chromosomes & Cancer, 64(5), Article e70055.","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"1","key":"10364_CR178","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/dermatopathology10010003","volume":"10","author":"LP Secco","year":"2023","unstructured":"Secco, L. P., Libbrecht, L., Seijnhaeve, E., Eggers, S., Dekairelle, A. F., & De Roo, A. K. (2023). Epithelioid fibrous histiocytoma with CARS-ALK fusion: First case report. Dermatopathology (Basel)., 10(1), 25\u201329.","journal-title":"Dermatopathology (Basel)."},{"key":"10364_CR179","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf221","author":"JY Lee","year":"2025","unstructured":"Lee, J. Y., Lee, K. R., Na, S., Na, H. Y., Lee, S., Kim, S. A., et al. (2025). ALK-positive adult histiocytosis with a TFG-ALKfusion gene. The Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf221","journal-title":"The Oncologist"},{"issue":"1","key":"10364_CR180","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001115","volume":"3","author":"VR Holla","year":"2017","unstructured":"Holla, V. R., Elamin, Y. Y., Bailey, A. M., Johnson, A. M., Litzenburger, B. C., Khotskaya, Y. B., et al. (2017). ALK: A tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud., 3(1), Article a001115.","journal-title":"Cold Spring Harb Mol Case Stud."},{"issue":"3","key":"10364_CR181","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/(SICI)1098-2264(199603)15:3<173::AID-GCC5>3.0.CO;2-#","volume":"15","author":"M Ladanyi","year":"1996","unstructured":"Ladanyi, M., & Cavalchire, G. (1996). Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site. Genes, Chromosomes & Cancer, 15(3), 173\u2013177.","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"9","key":"10364_CR182","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2401878","volume":"14","author":"HG Drexler","year":"2000","unstructured":"Drexler, H. G., Gignac, S. M., von Wasielewski, R., Werner, M., & Dirks, W. G. (2000). Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia, 14(9), 1533\u20131559.","journal-title":"Leukemia"},{"issue":"4","key":"10364_CR183","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0002-9440(10)62574-6","volume":"160","author":"L Hern\u00e1ndez","year":"2002","unstructured":"Hern\u00e1ndez, L., Be\u00e0, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., et al. (2002). Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: Identification of a new TFG-ALK(XL) chimeric gene with transforming activity. American Journal of Pathology, 160(4), 1487\u20131494.","journal-title":"American Journal of Pathology"},{"issue":"41","key":"10364_CR184","doi-asserted-by":"publisher","first-page":"26543","DOI":"10.18632\/oncotarget.25489","volume":"9","author":"M Krumbholz","year":"2018","unstructured":"Krumbholz, M., Woessmann, W., Zierk, J., Seniuk, D., Ceppi, P., Zimmermann, M., et al. (2018). Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma. Oncotarget, 9(41), 26543\u201326555.","journal-title":"Oncotarget"},{"issue":"1","key":"10364_CR185","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","volume":"37","author":"S Peters","year":"2026","unstructured":"Peters, S., Camidge, R., Dziadziuszko, R., Gadgeel, S., Shaw, A. T., Kim, D. W., et al. (2026). Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study. Annals of Oncology, 37(1), 92\u2013103.","journal-title":"Annals of Oncology"},{"issue":"5","key":"10364_CR186","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"C Bresler Scott","year":"2014","unstructured":"Bresler Scott, C., Weiser Daniel, A., Huwe Peter, J., Park Jin, H., Krytska, K., Ryles, H., et al. (2014). ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell, 26(5), 682\u2013694.","journal-title":"Cancer Cell"},{"issue":"17","key":"10364_CR187","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-09-2660","volume":"16","author":"S De Brouwer","year":"2010","unstructured":"De Brouwer, S., De Preter, K., Kumps, C., Zabrocki, P., Porcu, M., Westerhout, E. M., et al. (2010). Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clinical Cancer Research., 16(17), 4353\u20134362.","journal-title":"Clinical Cancer Research."},{"issue":"25","key":"10364_CR188","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1200\/JCO.2013.54.0674","volume":"32","author":"G Schleiermacher","year":"2014","unstructured":"Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., et al. (2014). Emergence of new ALK mutations at relapse of neuroblastoma. Journal of Clinical Oncology., 32(25), 2727\u20132734.","journal-title":"Journal of Clinical Oncology."},{"issue":"20","key":"10364_CR189","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/s41388-022-02301-1","volume":"41","author":"M Hiwatari","year":"2022","unstructured":"Hiwatari, M., Seki, M., Matsuno, R., Yoshida, K., Nagasawa, T., Sato-Otsubo, A., et al. (2022). Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma. Oncogene, 41(20), 2789\u20132797.","journal-title":"Oncogene"},{"issue":"12","key":"10364_CR190","first-page":"2776","volume":"59","author":"CA Griffin","year":"1999","unstructured":"Griffin, C. A., Hawkins, A. L., Dvorak, C., Henkle, C., Ellingham, T., & Perlman, E. J. (1999). Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer research., 59(12), 2776\u20132780.","journal-title":"Cancer research."},{"issue":"5","key":"10364_CR191","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch, H., Amin, M. B., Berney, D. M., Comp\u00e9rat, E. M., Gill, A. J., Hartmann, A., et al. (2022). The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014Part A: Renal, penile, and testicular tumours. European Urology, 82(5), 458\u2013468.","journal-title":"European Urology"},{"issue":"2","key":"10364_CR192","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5114\/pjp.2018.76693","volume":"69","author":"N Kuroda","year":"2018","unstructured":"Kuroda, N., Sugawara, E., Kusano, H., Yuba, Y., Yorita, K., & Takeuchi, K. (2018). A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects. Polish Journal of Pathology, 69(2), 109\u2013113.","journal-title":"Polish Journal of Pathology"},{"key":"10364_CR193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00185","volume":"2","author":"JJ Tao","year":"2018","unstructured":"Tao, J. J., Wei, G., Patel, R., Fagan, P., Hao, X., Bridge, J. A., et al. (2018). ALK fusions in renal cell carcinoma: Response to entrectinib. JCO Precision Oncology, 2, 1\u20138.","journal-title":"JCO Precision Oncology"},{"issue":"6","key":"10364_CR194","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/PAS.0000000000000179","volume":"38","author":"NE Smith","year":"2014","unstructured":"Smith, N. E., Deyrup, A. T., Mari\u00f1o-Enriquez, A., Fletcher, J. A., Bridge, J. A., Illei, P. B., et al. (2014). VCL-ALK Renal cell carcinoma in children with sickle-cell trait: The eighth sickle-cell nephropathy? American Journal of Surgical Pathology., 38(6), 858\u2013863.","journal-title":"American Journal of Surgical Pathology."},{"issue":"6","key":"10364_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061476","volume":"13","author":"K Sankar","year":"2021","unstructured":"Sankar, K., Nagrath, S., & Ramnath, N. (2021). Immunotherapy for ALK-rearranged non-small cell lung cancer: Challenges inform promising approaches. Cancers, 13(6), Article 1476.","journal-title":"Cancers"},{"issue":"7213","key":"10364_CR196","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa, H., & Barber, G. N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature, 455(7213), 674\u2013678.","journal-title":"Nature"},{"issue":"7265","key":"10364_CR197","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa, H., Ma, Z., & Barber, G. N. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature, 461(7265), 788\u2013792.","journal-title":"Nature"},{"issue":"7","key":"10364_CR198","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12275-021-0638-2","volume":"59","author":"A Gao","year":"2021","unstructured":"Gao, A., Tang, H., Zhang, Q., Liu, R., Wang, L., Liu, Y., et al. (2021). Mst1\/2-ALK promotes NLRP3 inflammasome activation and cell apoptosis during Listeria monocytogenes infection. Journal of Microbiology, 59(7), 681\u2013692.","journal-title":"Journal of Microbiology"},{"key":"10364_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5689","author":"L Zeng","year":"2017","unstructured":"Zeng, L., Kang, R., Zhu, S., Wang, X., Cao, L., Wang, H., et al. (2017). ALK is a therapeutic target for lethal sepsis. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.aan5689","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10364_CR200","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12950-019-0208-0","volume":"16","author":"W Ge","year":"2019","unstructured":"Ge, W., Hu, Q., Fang, X., Liu, J., Xu, J., Hu, J., et al. (2019). LDK378 improves micro- and macro-circulation via alleviating STING-mediated inflammatory injury in a Sepsis rat model induced by Cecal ligation and puncture. Journal of Inflammation., 16(1), 3.","journal-title":"Journal of Inflammation."},{"issue":"4","key":"10364_CR201","first-page":"1605","volume":"96","author":"K Pulford","year":"2000","unstructured":"Pulford, K., Falini, B., Banham, A. H., Codrington, D., Roberton, H., Hatton, C., et al. (2000). Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, The Journal of the American Society of Hematology., 96(4), 1605\u20131607.","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"16","key":"10364_CR202","first-page":"3314","volume":"115","author":"K Ait-Tahar","year":"2010","unstructured":"Ait-Tahar, K., Damm-Welk, C., Burkhardt, B., Zimmermann, M., Klapper, W., Reiter, A., et al. (2010). Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase\u2013positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood, The Journal of the American Society of Hematology., 115(16), 3314\u20133319.","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"11","key":"10364_CR203","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.7150\/jca.15238","volume":"7","author":"C Damm-Welk","year":"2016","unstructured":"Damm-Welk, C., Siddiqi, F., Fischer, M., Hero, B., Narayanan, V., Camidge, D. R., et al. (2016). Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK. Journal of Cancer, 7(11), 1383\u20131387.","journal-title":"Journal of Cancer"},{"issue":"54","key":"10364_CR204","doi-asserted-by":"publisher","first-page":"92265","DOI":"10.18632\/oncotarget.21182","volume":"8","author":"MM Awad","year":"2017","unstructured":"Awad, M. M., Mastini, C., Blasco, R. B., Mologni, L., Voena, C., Mussolin, L., et al. (2017). Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget, 8(54), 92265.","journal-title":"Oncotarget"},{"key":"10364_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100164","volume":"6","author":"C Parisi","year":"2024","unstructured":"Parisi, C., Benitez, J. C., Lecourt, H., dall\u2019Olio, F. G., Aldea, M., Blanc-Durand, F., et al. (2024). Anti-ALK autoantibodies in patients with ALK-positive non-small cell lung cancer (NSCLC): A monocentric experience. Journal of Liquid Biopsy, 6, Article 100164.","journal-title":"Journal of Liquid Biopsy"},{"issue":"3","key":"10364_CR206","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ijc.21410","volume":"118","author":"K Ait-Tahar","year":"2006","unstructured":"Ait-Tahar, K., Cerundolo, V., Banham, A. H., Hatton, C., Blanchard, T., Kusec, R., et al. (2006). B and CTL responses to the ALK protein in patients with ALK-positive ALCL. International journal of cancer., 118(3), 688\u2013695.","journal-title":"International journal of cancer."},{"key":"10364_CR207","unstructured":"Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, et al. (2006). In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. haematologica, 91(1), 48\u201355."},{"issue":"6","key":"10364_CR208","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood.V99.6.2100","volume":"99","author":"L Passoni","year":"2002","unstructured":"Passoni, L., Scardino, A., Bertazzoli, C., Gallo, B., Coluccia, A. M., Lemonnier, F. A., et al. (2002). ALK as a novel lymphoma-associated tumor antigen: Identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood, 99(6), 2100\u20132106.","journal-title":"Blood"},{"key":"10364_CR209","doi-asserted-by":"crossref","unstructured":"V KS, Werner S, Hackstein H, Lennerz V, Reiter A, W\u00f6lfel T, et al. (2016). Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma. Clin Exp Immunol, 186(1), 96\u2013105.","DOI":"10.1111\/cei.12842"},{"issue":"6","key":"10364_CR210","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nm1769","volume":"14","author":"R Chiarle","year":"2008","unstructured":"Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D\u2019escamard, V., Forni, G., et al. (2008). The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature medicine., 14(6), 676\u2013680.","journal-title":"Nature medicine."},{"issue":"5","key":"10364_CR211","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/0008-5472.CAN-06-4427","volume":"67","author":"K Ait-Tahar","year":"2007","unstructured":"Ait-Tahar, K., Barnardo, M. C., & Pulford, K. (2007). CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer research., 67(5), 1898\u20131901.","journal-title":"Cancer research."},{"issue":"12","key":"10364_CR212","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein, H., Foss, H. D., D\u00fcrkop, H., Marafioti, T., Delsol, G., Pulford, K., et al. (2000). CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood, 96(12), 3681\u20133695.","journal-title":"Blood"},{"issue":"18","key":"10364_CR213","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1158\/0008-5472.CAN-05-4101","volume":"66","author":"FY-Y Hsu","year":"2006","unstructured":"Hsu, F.Y.-Y., Johnston, P. B., Burke, K. A., & Zhao, Y. (2006). The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase\u2013mediated JunB level in a cell type\u2013specific manner. Cancer Research, 66(18), 9002\u20139008.","journal-title":"Cancer Research"},{"issue":"8","key":"10364_CR214","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","volume":"98","author":"B Bisig","year":"2013","unstructured":"Bisig, B., de Reyni\u00e8s, A., Bonnet, C., Sujobert, P., Rickman, D. S., Marafioti, T., et al. (2013). CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica, 98(8), 1250.","journal-title":"Haematologica"},{"issue":"26","key":"10364_CR215","doi-asserted-by":"publisher","first-page":"9964","DOI":"10.1073\/pnas.0603507103","volume":"103","author":"M Kasprzycka","year":"2006","unstructured":"Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q., & Wasik, M. A. (2006). Nucleophosmin\/anaplastic lymphoma kinase (NPM\/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A., 103(26), 9964\u20139969.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"52","key":"10364_CR216","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., et al. (2008). Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America, 105(52), 20852\u201320857.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10364_CR217","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song, T. L., Nairism\u00e4gi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., et al. (2018). Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood, 132(11), 1146\u20131158.","journal-title":"Blood"},{"issue":"1","key":"10364_CR218","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","volume":"112","author":"A D\u2019Incecco","year":"2015","unstructured":"D\u2019Incecco, A., Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L., et al. (2015). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer, 112(1), 95\u2013102.","journal-title":"British Journal of Cancer"},{"issue":"17","key":"10364_CR219","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","volume":"21","author":"K Ota","year":"2015","unstructured":"Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., et al. (2015). Induction of PD-L1 expression by the EML4\u2013ALK oncoprotein and downstream signaling pathways in non\u2013small cell lung cancer. Clinical cancer research., 21(17), 4014\u20134021.","journal-title":"Clinical cancer research."},{"issue":"12","key":"10364_CR220","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/2326-6066.CIR-19-0056","volume":"7","author":"CY Oh","year":"2019","unstructured":"Oh, C. Y., Klatt, M. G., Bourne, C., Dao, T., Dacek, M. M., Brea, E. J., et al. (2019). ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research., 7(12), 1984\u20131997.","journal-title":"Cancer Immunology Research."},{"issue":"12","key":"10364_CR221","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio, E., Tai, W. T., Aroldi, A., Mecca, C., Landoni, E., N\u00fcesch, M., et al. (2023). ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell, 41(12), 2100\u201316.e10.","journal-title":"Cancer Cell"},{"issue":"10072","key":"10364_CR222","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(17)30124-1","volume":"389","author":"B Solomon","year":"2017","unstructured":"Solomon, B. (2017). First-line treatment options for ALK -rearranged lung cancer. The Lancet., 389(10072), 884\u2013886.","journal-title":"The Lancet."},{"key":"10364_CR223","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003316","author":"R Katayama","year":"2012","unstructured":"Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.3003316","journal-title":"Science Translational Medicine"},{"issue":"23","key":"10364_CR224","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine, 371(23), 2167\u20132177.","journal-title":"New England Journal of Medicine"},{"key":"10364_CR225","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2021.07.016","volume":"156","author":"P Sch\u00f6ffski","year":"2021","unstructured":"Sch\u00f6ffski, P., Kubickova, M., Wozniak, A., Blay, J.-Y., Strauss, S. J., Stacchiotti, S., et al. (2021). Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. European Journal of Cancer., 156, 12\u201323.","journal-title":"European Journal of Cancer."},{"issue":"10072","key":"10364_CR226","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"J-C Soria","year":"2017","unstructured":"Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., et al. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. The Lancet., 389(10072), 917\u2013929.","journal-title":"The Lancet."},{"issue":"12","key":"10364_CR227","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-21-1838","volume":"28","author":"LQM Chow","year":"2022","unstructured":"Chow, L. Q. M., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H. A., Wen, P. Y., et al. (2022). ASCEND-7: Efficacy and safety of ceritinib treatment in patients with ALK-positive non-small cell lung cancer metastatic to the brain and\/or leptomeninges. Clinical Cancer Research, 28(12), 2506\u201316.","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10364_CR228","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., et al. (2017). Alectinib versus crizotinib in untreated ALK -positive non\u2013small-cell lung cancer. New England Journal of Medicine., 377(9), 829\u2013838.","journal-title":"New England Journal of Medicine."},{"issue":"12","key":"10364_CR229","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., et al. (2021). Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L Trial. Journal of Thoracic Oncology., 16(12), 2091\u20132108.","journal-title":"Journal of Thoracic Oncology."},{"issue":"1","key":"10364_CR230","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed, Y. Y. (2019). Lorlatinib: First Global Approval. Drugs, 79(1), 93\u201398.","journal-title":"Drugs"},{"issue":"21","key":"10364_CR231","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., et al. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. New England Journal of Medicine., 383(21), 2018\u20132029.","journal-title":"New England Journal of Medicine."},{"key":"10364_CR232","doi-asserted-by":"publisher","first-page":"S1180","DOI":"10.1016\/j.annonc.2020.08.2282","volume":"31","author":"B Solomon","year":"2020","unstructured":"Solomon, B., Bauer, T. M., De Marinis, F., Felip, E., Goto, Y., Liu, G., et al. (2020). LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study. Annals of Oncology., 31, S1180\u2013S1181.","journal-title":"Annals of Oncology."},{"issue":"29","key":"10364_CR233","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon, B. J., Liu, G., Felip, E., Mok, T. S., Soo, R. A., Mazieres, J., et al. (2024). Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 42(29), 3400\u20133409.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10364_CR234","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello, S., Mazi\u00e8res, J., Oh, I.-J., De Castro, J., Migliorino, M. R., Helland, \u00c5., et al. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: Results from the phase III ALUR study. Annals of Oncology, 29(6), 1409\u20131416.","journal-title":"Annals of Oncology"},{"issue":"11","key":"10364_CR235","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., et al. (2021). Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase\u2212positive non\u2013small cell lung cancer: A randomized clinical trial. JAMA Oncology., 7(11), 1617.","journal-title":"JAMA Oncology."},{"key":"10364_CR236","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010168","author":"P Hofman","year":"2021","unstructured":"Hofman, P. (2021). Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: An update to a clinical routine practice. Cells. https:\/\/doi.org\/10.3390\/cells10010168","journal-title":"Cells"},{"issue":"10","key":"10364_CR237","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., et al. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discovery., 6(10), 1118\u20131133.","journal-title":"Cancer Discovery."},{"issue":"16","key":"10364_CR238","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.18.02236","volume":"37","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C.-C., Soo, R. A., et al. (2019). ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non\u2013small-cell lung cancer. Journal of Clinical Oncology., 37(16), 1370\u20131379.","journal-title":"Journal of Clinical Oncology."},{"issue":"6","key":"10364_CR239","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","volume":"3","author":"A Shiba-Ishii","year":"2022","unstructured":"Shiba-Ishii, A., Johnson, T. W., Dagogo-Jack, I., Mino-Kenudson, M., Johnson, T. R., Wei, P., et al. (2022). Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature cancer., 3(6), 710\u2013722.","journal-title":"Nature cancer."},{"issue":"1","key":"10364_CR240","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1508887","volume":"374","author":"AT Shaw","year":"2016","unstructured":"Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., et al. (2016). Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. New England Journal of Medicine., 374(1), 54\u201361.","journal-title":"New England Journal of Medicine."},{"key":"10364_CR241","first-page":"20","volume":"7","author":"D Poei","year":"2024","unstructured":"Poei, D., Ali, S., Ye, S., & Hsu, R. (2024). ALK inhibitors in cancer: Mechanisms of resistance and therapeutic management strategies. Cancer Drug Resistance., 7, 20.","journal-title":"Cancer Drug Resistance."},{"issue":"5","key":"10364_CR242","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., et al. (2012). Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non\u2013small cell lung cancer. Clinical cancer research., 18(5), 1472\u20131482.","journal-title":"Clinical cancer research."},{"key":"10364_CR243","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","volume":"158","author":"SS Zhang","year":"2021","unstructured":"Zhang, S. S., Nagasaka, M., Zhu, V. W., & Ou, S.-H.I. (2021). Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer, 158, 126\u2013136.","journal-title":"Lung Cancer"},{"issue":"6","key":"10364_CR244","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/1878-0261.13446","volume":"17","author":"M Elshatlawy","year":"2023","unstructured":"Elshatlawy, M., Sampson, J., Clarke, K., & Bayliss, R. (2023). EML4-ALK biology and drug resistance in non-small cell lung cancer: A new phase of discoveries. Molecular Oncology., 17(6), 950\u2013963.","journal-title":"Molecular Oncology."},{"issue":"1","key":"10364_CR245","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2159-8290.CD-24-1417","volume":"16","author":"A Diaz-Jimenez","year":"2026","unstructured":"Diaz-Jimenez, A., Shuldiner, E. G., Somogyi, K., Shih, K. Y., Gonz\u00e1lez-Velasco, \u00d3., Najajreh, M., et al. (2026). EML4-ALK variant-specific genetic interactions shape lung tumorigenesis. Cancer Discovery, 16(1), 46\u201365.","journal-title":"Cancer Discovery"},{"issue":"28","key":"10364_CR246","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","volume":"34","author":"T Yoshida","year":"2016","unstructured":"Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., et al. (2016). Differential crizotinib response duration among ALK fusion variants in ALK-positive non\u2013small-cell lung cancer. Journal of Clinical Oncology., 34(28), 3383\u20133389.","journal-title":"Journal of Clinical Oncology."},{"issue":"4","key":"10364_CR247","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/annonc\/mdw693","volume":"28","author":"C Woo","year":"2017","unstructured":"Woo, C., Seo, S., Kim, S., Jang, S., Park, K., Song, J., et al. (2017). Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer. Annals of Oncology., 28(4), 791\u2013797.","journal-title":"Annals of Oncology."},{"issue":"12","key":"10364_CR248","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.31275","volume":"142","author":"P Christopoulos","year":"2018","unstructured":"Christopoulos, P., Endris, V., Bozorgmehr, F., Elsayed, M., Kirchner, M., Ristau, J., et al. (2018). EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. International journal of cancer., 142(12), 2589\u20132598.","journal-title":"International journal of cancer."},{"issue":"12","key":"10364_CR249","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","volume":"36","author":"JJ Lin","year":"2018","unstructured":"Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., et al. (2018). Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. Journal of Clinical Oncology., 36(12), 1199\u20131206.","journal-title":"Journal of Clinical Oncology."},{"issue":"18","key":"10364_CR250","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","volume":"71","author":"T Sasaki","year":"2011","unstructured":"Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., et al. (2011). A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer research., 71(18), 6051\u20136060.","journal-title":"Cancer research."},{"issue":"3","key":"10364_CR251","first-page":"3071","volume":"17","author":"H Yang","year":"2019","unstructured":"Yang, H., Wang, F., Deng, Q., Xiao, D., He, P., Lin, X., et al. (2019). Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion. Oncology Letters., 17(3), 3071\u20133076.","journal-title":"Oncology Letters."},{"issue":"9","key":"10364_CR252","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm.3667","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., et al. (2014). Rationale for co-targeting IGF-1R and ALK in ALK fusion\u2013positive lung cancer. Nature medicine., 20(9), 1027\u20131034.","journal-title":"Nature medicine."},{"issue":"22","key":"10364_CR253","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-12-0392","volume":"18","author":"J Tanizaki","year":"2012","unstructured":"Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., et al. (2012). Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK\u2013positive non\u2013small cell lung cancer. Clinical cancer research., 18(22), 6219\u20136226.","journal-title":"Clinical cancer research."},{"issue":"1","key":"10364_CR254","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk, F., Chou, Y.-T., Cech, L., Fern\u00e1ndez-M\u00e9ndez, C., Yu, J., Olivas, V., et al. (2024). Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nature communications., 15(1), 3741.","journal-title":"Nature communications."},{"key":"10364_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101081","volume":"74","author":"A Diaz-Jimenez","year":"2024","unstructured":"Diaz-Jimenez, A., Ramos, M., Helm, B., Chocarro, S., Frey, D. L., Agrawal, S., et al. (2024). Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resist Updat., 74, Article 101081.","journal-title":"Drug Resist Updat."},{"key":"10364_CR256","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","volume":"146","author":"R Shi","year":"2020","unstructured":"Shi, R., Martins Filho, S. N., Li, M., Fares, A., Weiss, J., Pham, N.-A., et al. (2020). BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung Cancer, 146, 78\u201385.","journal-title":"Lung Cancer"},{"issue":"11","key":"10364_CR257","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., et al. (2020). MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clinical Cancer Research., 26(11), 2535\u20132545.","journal-title":"Clinical Cancer Research."},{"issue":"2","key":"10364_CR258","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41419-020-2307-5","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen, H., Lin, C., Peng, T., Hu, C., Lu, C., Li, L., et al. (2020). Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell death & disease., 11(2), 111.","journal-title":"Cell death & disease."},{"issue":"1","key":"10364_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-025-07513-3","volume":"16","author":"F Mart\u00edn","year":"2025","unstructured":"Mart\u00edn, F., Alcon, C., Mar\u00edn, E., Morales-S\u00e1nchez, P., Manzano-Mu\u00f1oz, A., D\u00edaz, S., et al. (2025). Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer. Cell Death & Disease., 16(1), 1\u201312.","journal-title":"Cell Death & Disease."},{"issue":"4","key":"10364_CR260","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/cas.70006","volume":"116","author":"T Utsumi","year":"2025","unstructured":"Utsumi, T., Mizuta, H., Seto, Y., Uchibori, K., Nishio, M., Okamoto, I., et al. (2025). AXL-mediated drug resistance in ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11 positive fibroblasts. Cancer Science, 116(4), 1034\u20131047.","journal-title":"Cancer Science"},{"issue":"5","key":"10364_CR261","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdw032","volume":"27","author":"N Takegawa","year":"2016","unstructured":"Takegawa, N., Hayashi, H., Iizuka, N., Takahama, T., Ueda, H., Tanaka, K., et al. (2016). Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Annals of Oncology, 27(5), 953\u2013955.","journal-title":"Annals of Oncology"},{"key":"10364_CR262","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2018.11.027","volume":"127","author":"S Park","year":"2019","unstructured":"Park, S., Han, J., & Sun, J. M. (2019). Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. Lung Cancer, 127, 66\u201368.","journal-title":"Lung Cancer"},{"key":"10364_CR263","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","volume":"102","author":"D Levacq","year":"2016","unstructured":"Levacq, D., D\u2019Haene, N., de Wind, R., Remmelink, M., & Berghmans, T. (2016). Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Lung Cancer, 102, 38\u201341.","journal-title":"Lung Cancer"},{"issue":"5","key":"10364_CR264","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/pin.12782","volume":"69","author":"K Koyama","year":"2019","unstructured":"Koyama, K., Katsurada, N., Jimbo, N., Tachihara, M., Tamura, D., Nakata, K., et al. (2019). Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma. Pathology International, 69(5), 294\u2013299.","journal-title":"Pathology International"},{"key":"10364_CR265","doi-asserted-by":"crossref","unstructured":"Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, et al. (2018). Mutations in EMT-related genes in ALK positive crizotinib resistant non-small cell lung cancers. Cancers (Basel), 10(1), 10.","DOI":"10.3390\/cancers10010010"},{"key":"10364_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110264","volume":"92","author":"J Shen","year":"2022","unstructured":"Shen, J., Meng, Y., Wang, K., Gao, M., Du, J., Wang, J., et al. (2022). EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3\/Slug signaling. Cellular Signalling, 92, Article 110264.","journal-title":"Cellular Signalling"},{"issue":"7","key":"10364_CR267","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/0008-5472.CAN-18-2052","volume":"79","author":"K Fukuda","year":"2019","unstructured":"Fukuda, K., Takeuchi, S., Arai, S., Katayama, R., Nanjo, S., Tanimoto, A., et al. (2019). Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Research, 79(7), 1658\u20131670.","journal-title":"Cancer Research"},{"issue":"1","key":"10364_CR268","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cbin.12249","volume":"49","author":"Y Yang","year":"2025","unstructured":"Yang, Y., Yang, H., Gao, Y., Yang, Q., Zhu, X., Miao, Q., et al. (2025). EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial\u2013mesenchymal transition mediated by MDM2\/MEK\/ERK signal axis. Cell Biology International., 49(1), 55\u201367.","journal-title":"Cell Biology International."},{"key":"10364_CR269","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ebiom.2015.12.009","volume":"3","author":"R Katayama","year":"2016","unstructured":"Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., et al. (2016). P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. eBioMedicine, 3, 54\u201366.","journal-title":"eBioMedicine"},{"issue":"5","key":"10364_CR270","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","volume":"74","author":"T Kodama","year":"2014","unstructured":"Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014). Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemotherapy and Pharmacology, 74(5), 1023\u20131028.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"11","key":"10364_CR271","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","volume":"29","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel, S., Peters, S., Mok, T., Shaw, A. T., Kim, D. W., Ou, S. I., et al. (2018). Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of Oncology, 29(11), 2214\u20132222.","journal-title":"Annals of Oncology"},{"issue":"40","key":"10364_CR272","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1038\/s41388-022-02453-0","volume":"41","author":"M Hu","year":"2022","unstructured":"Hu, M., Bao, R., Lin, M., Han, X. R., Ai, Y. J., Gao, Y., et al. (2022). ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3. Oncogene, 41(40), 4547\u20134559.","journal-title":"Oncogene"},{"issue":"1","key":"10364_CR273","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40170-025-00400-7","volume":"13","author":"AK Daum","year":"2025","unstructured":"Daum, A. K., Schlicker, L., Schneider, M. A., Muley, T., Klingm\u00fcller, U., Schulze, A., et al. (2025). Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. Cancer & Metabolism, 13(1), 28.","journal-title":"Cancer & Metabolism"},{"issue":"4","key":"10364_CR274","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jtho.2016.12.003","volume":"12","author":"S Schmid","year":"2017","unstructured":"Schmid, S., Gautschi, O., Rothschild, S., Mark, M., Froesch, P., Klingbiel, D., et al. (2017). Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors (TKIs). Journal of Thoracic Oncology, 12(4), 681\u2013688.","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10364_CR275","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-0699","volume":"20","author":"JJ Yang","year":"2014","unstructured":"Yang, J. J., Zhang, X. C., Su, J., Xu, C. R., Zhou, Q., Tian, H. X., et al. (2014). Lung cancers with concomitant EGFR mutations and ALK rearrangements: Diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clinical Cancer Research, 20(5), 1383\u20131392.","journal-title":"Clinical Cancer Research"},{"issue":"15","key":"10364_CR276","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.30677","volume":"123","author":"L Zhang","year":"2017","unstructured":"Zhang, L., Jiang, T., Li, X., Wang, Y., Zhao, C., Zhao, S., et al. (2017). Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK\/ROS1 fusion-positive non-small cell lung cancer. Cancer, 123(15), 2927\u201335.","journal-title":"Cancer"},{"issue":"15","key":"10364_CR277","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","volume":"29","author":"DB Costa","year":"2011","unstructured":"Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W. L., Shen, Z., Tan, W., et al. (2011). CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. Journal of Clinical Oncology, 29(15), e443\u2013e445.","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10364_CR278","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","volume":"20","author":"BW Murray","year":"2021","unstructured":"Murray, B. W., Zhai, D., Deng, W., Zhang, X., Ung, J., Nguyen, V., et al. (2021). TPX-0131, a Potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Molecular Cancer Therapeutics, 20(9), 1499\u20131507.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10364_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108490","volume":"204","author":"JWT van der Wel","year":"2025","unstructured":"van der Wel, J. W. T., & de Langen, A. J. (2025). Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting. Lung Cancer, 204, Article 108490.","journal-title":"Lung Cancer"},{"issue":"3","key":"10364_CR280","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","volume":"59","author":"X Sun","year":"2020","unstructured":"Sun, X., & Rao, Y. (2020). PROTACs as potential therapeutic agents for cancer drug resistance. Biochemistry, 59(3), 240\u2013249.","journal-title":"Biochemistry"},{"key":"10364_CR281","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","volume":"151","author":"C Zhang","year":"2018","unstructured":"Zhang, C., Han, X. R., Yang, X., Jiang, B., Liu, J., Xiong, Y., et al. (2018). Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). European Journal of Medicinal Chemistry, 151, 304\u2013314.","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10364_CR282","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061260","author":"E Eriau","year":"2021","unstructured":"Eriau, E., Paillet, J., Kroemer, G., & Pol, J. G. (2021). Metabolic reprogramming by reduced calorie intake or pharmacological caloric restriction mimetics for improved cancer immunotherapy. Cancers. https:\/\/doi.org\/10.3390\/cancers13061260","journal-title":"Cancers"},{"issue":"23","key":"10364_CR283","doi-asserted-by":"publisher","first-page":"34442","DOI":"10.18632\/oncotarget.9120","volume":"7","author":"L Li","year":"2016","unstructured":"Li, L., Wang, Y., Peng, T., Zhang, K., Lin, C., Han, R., et al. (2016). Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget, 7(23), 34442\u201334452.","journal-title":"Oncotarget"},{"key":"10364_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114345","volume":"183","author":"AR Bland","year":"2021","unstructured":"Bland, A. R., Shrestha, N., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2021). The effect of metformin in EML(4)-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochemical Pharmacology, 183, Article 114345.","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10364_CR285","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41419-020-2307-5","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen, H., Lin, C., Peng, T., Hu, C., Lu, C., Li, L., et al. (2020). Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell Death & Disease, 11(2), 111.","journal-title":"Cell Death & Disease"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10364-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10364-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10364-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:01:45Z","timestamp":1787133705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10364-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":285,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10364"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10364-9","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing financial or non-financial interests to disclose that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"61"}}